Next indication a long way off...TLT needs to remain laser-focussed (pun intended) on NMIBC for at least another year or so, before delving into Ph1 for lung, brain, or any other of the numerous cancers that can be treated with its photodynamic therapies.
At the same time, another year should be sufficient to determine whether the cool laser business is worth pursuing. In other words, TLT should have the discipline to make either a GO or NO-GO decison on that aspect of the company.
IMO, Dr Shirazi is bringing that much-needed discipline to Theralase. Unlike RDW, he provides shareholders with a more objective perspective of the cool laser division.
The best case scenario for that business is that it pays its own way or even ekes out a profit.